Brief: Affimed completes TandAb development candidate activities

Affimed NV

24/03/2015 10:09

March 24 (Reuters) - Affimed NV  AFMD.O : 
 * Completes tandab development candidate activities meeting amphivena's and 
   janssen's criteria and achieves milestone ahead of schedule 
 * Milestone represents the development candidate selection against an 
   undisclosed target for the treatment of a certain hematologic malignancy 
 * Is due to receive a milestone payment of EUR7.5 million from amphivena which 
   will be paid in three installments 
 * Says in addition, in its role as amphivena shareholder, Affimed will invest 
   its third and last tranche of $0.36 million 
 
 * Source text for Eikon  ID:nGNXVDCJNa  
 
 * Further company coverage  AFMD.O   
 
 ((Bengaluru Newsroom; +1 646 223 8780))